
Ancora Heart Stock
Ancora Heart is dedicated to helping people with heart failure feel better and live longer.
Sign up today and learn more about Ancora Heart Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Ancora Heart Stock
Ancora Heart is dedicated to helping people with heart failure feel better and live longer. Ancora Heart developed the AccuCinch System, an investigational therapy designed to repair the enlarged left ventricle targeting the underlying cause of heart failure. The AccuCinch heart failure treatment was created to benefit the millions of patients who otherwise have no minimally invasive option available to them.
Funding History
April 2010 | $30.0M |
---|---|
May 2018 | $17.8M |
December 2018 | $23.5M |
July 2021 | $80.0M |
Management
Board Observer
Naveen Yalamanchi
President and CEO
Jeffrey M. Closs
Vice President, Clinical Marketing
Bart Beasley
CTO
Russel Sampson
Vice President, Regulatory Affairs and Quality Assurance
Mike Fritz
Press
biospace - Apr, 19 2023
Ancora Heart Inc. and egnite, Inc. Announce Strategic Partnership to Accelerate Clinical Trial Enrollment for Heart Failure Patientsfiercebiotech - Mar, 24 2023
Abbott, Ancora Heart score study wins with heart failure devicesbiospace - Oct, 12 2022
Ancora Heart Appoints David J. Tucker as Chief Financial Officermassdevice - Jul, 13 2022
Ancora Heart’s AccuCinch ventricular restoration system wins FDA breakthrough nodbiospace - Jun, 23 2022
Ancora Heart Appoints Mark Miles as Chief Commercial Officerfiercebiotech - Jul, 19 2021
Ancora Heart stitches up $80M for its ventricle-reshaping treatment for heart failurebiospace - Jul, 19 2021
Ancora Heart Secures $80 Million in Financingmassdevice - Jul, 1 2020
Ancora Heart wins IDE for ventricular restoration systembioworld - Jul, 1 2020
Ancora Heart gets FDA nod for Accucinch pivotal trialbioportfolio - May, 31 2019
Ancora Heart enrols first patient in early feasibility study of AccuCinch SystemEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase